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Discoveries of physiology often precede anatomy in immunol-
ogy research. Forty-five years before the discovery of IgE,
Prausnitz and Küstner found that allergy can be transferred by
sera from allergic patients in 1921 [1]. Tested by erythema-
wheal assays, this serum fraction was named Breagin.^ With
the advances in electrophoresis and ultracentrifugation between
the 1930s and 1960s, IgG, IgM, IgA, and IgD were sequential-
ly discovered. By the end of 1964, most immunologists and
allergists believed that reagin is an allergen-specific IgA anti-
body. Eventually, in 1966, Ishizaka et al. discovered the immu-
noglobulin responsible for allergy—IgE, named after the ery-
thema-wheal. IgE was the last immunoglobulin discovered due
to its over 1000 times lower blood concentration in healthy
controls compared with the other immunoglobulin classes.
Although scarce, IgE characteristically has rapid, potent, and
broad effects through FcεRI and CD23 on a wide range of cell
types [2]. The evolutionary persistence of IgE suggests an im-
portant role in host defense [2]. IgE was shown to opsonize
Schistosoma mansoni for killing by eosinophils, to induce
strong responses of skin mast cells and basophils to arthropods
bites, and to activate mast cells to release proteases that neu-
tralize venoms [2]. In sharp contrast to the abundant studies on
increased IgE levels in the context of allergy, the clinical im-
plication of decreased IgE levels remain largely neglected. In
this issue, Lawrence et al. report a frequent lack of IgE in
addition to other immunoglobulins in the majority of common
variable immunodeficiency (CVID) patients. This should ignite
new research into host defense functions of IgE [3].
CVID is themost common severe primary immunodeficiency
in theworld, with prevalence as high as 3.8–7.7:100,000 [4]. The
accurate differentiation of CVID from secondary antibody defi-
ciency is particularly imperative because adequately substituted
patients on average live some 30 years longer than historical
controls. Giving IgG replacement therapy to for example asth-
matics with steroid-induced hypogammaglobulinemia may
cause severe side effects [5]. Despite a rather uniform phenotype,
there are multiple and variable available diagnostic criteria for
CVID [3, 4]. Much of this diagnostic confusion stems from
variable cutoffs for normalcy used for immunoglobulin classes
IgG, IgA, and IgM, as well as for specific antibodies, especially
for polysaccharide responses against pneumococcal antigens
[3–5]. Typically, CVID patients have low IgG, low IgA, and
specific antibody deficiency. However, at least 1.3% of primary
antibody-deficient patients present with only IgG and IgM defi-
ciency together with suboptimal specific antibody responses [4].
Secondary antibody deficiency due to the use of agents like
rituximab or glucocorticoids much more commonly presents
with such a combination of low Ig classes. Differentiating prima-
ry and secondary antibody deficiencies is also imperative for
various other purposes, such as for epidemiologic and genetic
studies. Consequently, the search for differentiation markers has
been a long struggle in the field. Currently, anti-pneumococcal
antibody responses are the favored specific marker for primary
CVID. However, the diagnostic use of anti-pneumococcal anti-
body responses is still largely limited to the same serotypes in-
cluded in conjugated pneumococcal vaccines. Therefore, their
results are difficult to interpret in previously vaccinated children
and elderly people. As alternatives, anti-Salmonella antibody
responses and serum allohemagglutinins have been used to help
in the differential diagnosis of CVID. However, these sadly seem
to perform suboptimally [5]. Recently, reduced levels of serum
free light chains were also proposed to function as differentiation
markers for CVID [6].
The report of low serum IgE in CVID patients is thus a
valuable observation for clinical diagnosis. By using contem-
porary accredited methods traceable to WHO reference prepa-
ration 75/502, Lawrence et al. found that serum IgE was lower
than 2 IU/ml in 75.6% of CVID patients tested. In fact, CVID
was associated with very low IgE already over 45 years ago [7].
Its use for diagnostic purposes was at that time not explored
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further, likely since it did not differentiate between IgA defi-
ciency patients with or without infection susceptibility [8].
Lawrence et al. further show that low levels of serum IgE are
useful in differentiating primary and secondary antibody im-
munodeficiencies. Results from our cohort largely corroborate
theirs: the prevalences of undetectable IgE were 79% for prob-
able CVID, 38% for possible CVID and 50% for secondary
hypogammaglobulinemia after lymphoma therapy
(unpublished) [4]. Since the use of agents like rituximab and
glucocorticoids cause typical changes into B cell differential, its
use together with serum IgE levels could greatly aid in differenti-
ating secondary hypogammaglobulinemia from primary CVID.
Besides its potential and far-ranging clinical implications, this
report remains intriguing also for basic studies on IgE production
in humans. In other antibody responses, germinal center B cells
undergo clonal expansion, somatic hypermutation (SHM), class
switch recombination (CSR), and generation of long-term mem-
ory B cells. This process is different for IgE-producing B cells.
Upon activation and initial expansion, IgE-expressing B cells
either rapidly transform into plasma cells or are subject to imme-
diate apoptosis. The generation of high-affinity IgE occurs in a
unique way, in which B cells undergo first IgM to IgG, and then
IgG to IgE CSR, also known as the sequential CSR [2]. This
unique process results in two features of IgE production: 1. Most
of the high-affinity IgE originates from IgG (or IgA)-expressing
B cell lineages; 2. IgE memory resides in IgG-expressing mem-
ory B cells. Although direct CSR exists in both human and
mouse, more and more recent data showed that the majority of
IgE in humans is produced through sequential CSR [9, 10].
Therefore, decreased IgG and IgE levels might reflect the insuf-
ficient memory B cell pool observed in a large proportion of
CVID patients. Moreover, low serum IgE together with low
IgG might reflect a more general defect in the activity of
activation-induced cytidine deaminase (AID). AID generates
mutations in germinal center B cells to initiate both CSR and
SHM. In the human constant heavy chain locus, heavy chain
genes reside in the order of IGHM-IGHG3-IGHG1-IGHE1_ps-
IgHA1-IGH_ps-IGHG2-IGHG4-IGHE-IGHA2. Interestingly, in
CVID patients, the genes more distal from the heavy chain locus
enhancer and regulatory regions were thus expressed more poor-
ly, reflected in the increased IgG1/IgG4 ratio and extremely low
IgE levels described by the authors. Therefore, defects in AID
activity or impairments after CSR at the stage when the proximal
heavy chains are cut out from the germline DNA could poten-
tially explain the overall decrease in the production of immuno-
globulins and memory B cells in CVID.
In addition to total serum IgE, the authors were unable to
detect circulating antigen-specific IgE in CVID patients. This
was observed despite the fact that in the USIDNET cohort the
rates of self-reported and/or physician-diagnosed allergy were
substantial, as discussed by the authors. Interestingly, clinical
allergy together with positive responses to bronchial provoca-
tion tests with allergens has been reported in CVID patients
with undetectable serum IgE [11]. How such Bpseudoallergic^
reactions could be maintained, or even worsened, in CVID
patients after the onset of disease seems puzzling. Also, as
intriguing as the low serum IgE levels reported in CVID pa-
tients are, we should not neglect to study those over 3% of
controls with undetectable serum IgE reported here and previ-
ously [3, 12]. These individuals, who presumably have normal
levels of other classes of immunoglobulins and normal num-
bers of total B cells, will be the key to understanding the spe-
cific role of IgE in host defense. We thus hope that this report
will eventually lead into better definitions for CVID, as well as
trigger more research into the physiologic functions of IgE.
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